Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Australian ChemGenex Readies Omapro For Second NDA Despite U.S. FDA Setbacks

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - Australian-headquartered ChemGenex has completed pivotal trials for Omapro for third-line treatment for chronic myeloid leukemia for patients who have failed multiple tyrosine kinase inhibitors; the company expects to file its application with U.S. FDA while its NDA for second-line treatment for CML in patients with the Brc-Abl T315I is still under review
Advertisement

Related Content

Australia's ChemGenex Reaches Agreement With U.S. FDA To Re-file Omapro NDA For Third-Line CML Treatment
Australia's ChemGenex Reaches Agreement With U.S. FDA To Re-file Omapro NDA For Third-Line CML Treatment
No Additional Omapro Trials Needed, U.S. FDA Tells Australian ChemGenex In Complete Response Letter
U.S. FDA Says Australian ChemGenex Needs Companion Diagnostic For Omapro
Australian ChemGenex's Omapro Faces Scaled Back Efficacy Claims After Trial Shortcomings
Australian ChemGenex's Omapro Faces Scaled Back Efficacy Claims After Trial Shortcomings
Advertisement
UsernamePublicRestriction

Register

SC074989

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel